Is it now time to prepare psychiatry for a psychedelic future?

IF 8.7 1区医学 Q1 PSYCHIATRY

British Journal of Psychiatry Pub Date : 2024-08-01 DOI:10.1192/bjp.2024.76

David Nutt, Ilana Crome, Allan H Young

引用次数: 0

Abstract

Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these communities might respond to these developments.

查看原文本刊更多论文

现在是精神病学为迷幻未来做好准备的时候了吗？

澳大利亚刚刚将两种受联合国精神药物公约管制的药物--迷幻药和亚甲二氧基甲基安非他明--重新列表，分别作为治疗难治性抑郁症和创伤后应激障碍的药物。本专题探讨了这些发展的原因，它们给精神病学界带来的机遇和挑战，以及这些界别如何与医疗系统一起应对这些发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Psychiatry 医学-精神病学

CiteScore

13.70

自引率

1.90%

发文量

184

审稿时长

4-8 weeks

期刊介绍： The British Journal of Psychiatry (BJPsych) is a renowned international journal that undergoes rigorous peer review. It covers various branches of psychiatry, with a specific focus on the clinical aspects of each topic. Published monthly by the Royal College of Psychiatrists, this journal is dedicated to enhancing the prevention, investigation, diagnosis, treatment, and care of mental illness worldwide. It also strives to promote global mental health. In addition to featuring authoritative original research articles from across the globe, the journal includes editorials, review articles, commentaries on contentious issues, a comprehensive book review section, and a dynamic correspondence column. BJPsych is an essential source of information for psychiatrists, clinical psychologists, and other professionals interested in mental health.